Mayo Clinic, ImpediMed team for better disease monitoring tech

ImpediMed and Mayo Clinic have joined forces to develop new solutions for the fluid status and body composition monitoring technology in additional disease indications.

The three-year joint development agreement isn't the start of a relationship between the two, as ImpediMed and Mayo had entered into a five year strategic agreement for clinical research in May this year.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The tech from ImpediMed uses bioimpedance spectroscopy (BIS) to send 256 unique frequencies through the body. Those frequencies help to assess intra- and extracellular fluid. Small fluid changes, if detected, could tip off healthcare providers and help detect and manage chronic disease in patients.

Since 2015 Mayo Clinic hospital in Florida has been participating in a randomized controlled study that analyzed BIS technology’s effectiveness when identifying lymphedema early on.

Fluid management is critical in multiple clinical areas according to Rick Carreon, the managing director and CEO of ImpediMed. He said in a statement that company’s goad with the Mayo partnership is “to uncover new solutions to increase the quality of life for patients. In order to achieve this, we must develop solutions that are both clinically relevant and cost efficient.”

According to ImpediMed, there is quite a bit of potential for a range of application for BIS technology, including cardiology and nephrology. Mayo Clinic and ImpediMed will be working together to develop new products and address changing needs of patients with chronic diseases. The duo also aims to improve quality, outcomes and costs of patient care.

"By working together we hope to continue to improve care and reduce costs, across additional episodes of care,” said Andy Danielsen, vice chair of Mayo Clinic Ventures.

- here's the press release

Related Article: 
Aussie ImpediMed raises $57M just after U.S. launch of early Dx tool for lymphedema in cancer


Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.